Chimerix (NASDAQ:CMRX) Stock Passes Below 200-Day Moving Average of $0.95

Chimerix, Inc. (NASDAQ:CMRX) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.95 and traded as low as $0.86. Chimerix shares last traded at $0.88, with a volume of 177,984 shares trading hands.

Analyst Ratings Changes

Several research analysts recently issued reports on CMRX shares. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Chimerix in a report on Wednesday, August 14th. StockNews.com upgraded Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st. Finally, Wedbush restated an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a research note on Tuesday, August 13th.

Chimerix Price Performance

The stock has a market capitalization of $78.43 million, a PE ratio of -0.94 and a beta of 1.12. The stock’s fifty day moving average is $0.90 and its 200-day moving average is $0.95.

Chimerix (NASDAQ:CMRX) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 46.35%. The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $1.26 million. During the same period in the prior year, the company posted ($0.21) EPS. On average, analysts forecast that Chimerix, Inc. will post -0.86 EPS for the current year.

Institutional Trading of Chimerix

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Koshinski Asset Management Inc. purchased a new position in Chimerix in the 1st quarter valued at $42,000. Marquette Asset Management LLC raised its position in shares of Chimerix by 24.3% in the first quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 22,709 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Chimerix in the second quarter worth about $137,000. Pale Fire Capital SE boosted its position in Chimerix by 113.6% during the fourth quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 112,318 shares during the last quarter. Finally, Vestal Point Capital LP purchased a new stake in Chimerix during the 4th quarter valued at about $1,348,000. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.